CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Level 4 - case-series / case-control
Case series without a control group
PubMed 38381673 · doi:10.1056/NEJMoa2308917
What was done
Fifteen patients with severe systemic lupus erythematosus (SLE; n = 8), idiopathic inflammatory myositis (n = 3), or systemic sclerosis (n = 4) received a single infusion of CD19 chimeric antigen receptor (CAR) T cells after lymphodepletion with fludarabine and cyclophosphamide. Clinical efficacy was assessed up to 2 years using disease-specific criteria (DORIS remission for SLE, ACR-EULAR major clinical response for myositis, and EUSTAR activity index for systemic sclerosis), alongside safety monitoring for cytokine release syndrome, neurotoxicity, and infections.
What was found
Over a median follow-up of 15 months (range, 4 to 29), the mean duration of B-cell aplasia was 112 ± 47 days. All 8 patients with SLE achieved DORIS remission, all 3 patients with myositis achieved an ACR-EULAR major clinical response, and all 4 patients with systemic sclerosis experienced reductions in EUSTAR activity scores. Immunosuppressive medications were completely discontinued in all 15 patients. Adverse events included grade 1 cytokine release syndrome (CRS) in 10 patients, grade 2 CRS in 1 patient, grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) in 1 patient, and pneumonia requiring hospitalization in 1 patient.
Why it matters
This study provides early proof-of-concept that CD19 CAR T-cell therapy can reset B-cell immunity and achieve drug-free clinical remission across multiple severe, refractory autoimmune conditions.
Limits
The study is an uncontrolled, open-label case series with a very small sample size (15 patients across three distinct disease entities). Follow-up was relatively short (median 15 months), precluding conclusions about long-term durability of remission, late relapse after B-cell recovery, or rare serious adverse effects.
Cited by
- supports CAR-T cells engineered to eliminate B cells, which are used to treat B-cell leukemias, are showing strong responses in early clinical trials for systemic lupus erythematosus and other autoimmune diseases.